ViiV’s Dovato Matches Biktarvy in Head-to-Head HIV Study — ViiV Healthcare Limited

Event summary

ViiV Healthcare’s Dovato (DTG/3TC) demonstrated non-inferior efficacy to Gilead’s Biktarvy (BIC/FTC/TAF) in a phase IIIb study of treatment-naïve HIV patients.
The VOGUE study randomized 509 participants, with 89% of Dovato recipients achieving viral suppression vs. 92% for Biktarvy at Week 48.
No treatment-emergent resistance was observed in either arm, reinforcing DTG/3TC’s high barrier to resistance.
The study included patients with high viral loads or low CD4+ cell counts, broadening the applicability of findings.

The big picture

The study underscores a growing trend toward simplified HIV regimens, with ViiV positioning Dovato as a viable alternative to Gilead’s Biktarvy. This head-to-head comparison could reshape treatment preferences, particularly for patients prioritizing fewer daily medications without compromising efficacy. The absence of resistance in either arm further strengthens the case for two-drug regimens in HIV management.

What we're watching

Market Positioning: Whether ViiV can leverage these results to challenge Gilead’s dominance in the HIV treatment market, particularly for simpler regimens.
Regulatory Impact: The pace at which regulatory agencies may expand Dovato’s indications based on this head-to-head comparison data.
Long-Term Adherence: How the two-drug regimen’s simplicity and resistance profile will affect long-term patient adherence and outcomes.